Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Clinical Trial
. 1987 Apr 15;65(8):369-72.
doi: 10.1007/BF01745575.

Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulin

B Emmerich, E Hiller, F Woitinas, P A Maubach, H Riess, C Nerl, R G Geursen
Clinical Trial

Dose-response relationship in the treatment of idiopathic thrombocytopenic purpura with intravenous immunoglobulin

B Emmerich et al. Klin Wochenschr. .

Abstract

The dose-response relationship in the intravenous immunoglobulin treatment of idiopathic thrombocytopenic purpura was studied in 20 adult patients in a multicenter prospective crossover trial. The rate of response increases from 3 out of 11 (27%) to 6 out of 10 treatment periods (60%) by raising the 7S-IgG dose given on 5 consecutive days from 164.50 +/- 24.55 to 359.65 +/- 58.62 mg/kg body weight. The onset and duration of response as well as the peak platelet count were found to be independent of the doses. A long-term benefit induced by intravenous immunoglobulin treatment could be achieved in 2 out of 14 patients with chronic idiopathic thrombocytopenic purpura.

PubMed Disclaimer

Similar articles

See all similar articles

Cited by

References

    1. Vox Sang. 1983;45(2):144-54 - PubMed
    1. N Engl J Med. 1982 May 27;306(21):1254-8 - PubMed
    1. Thromb Haemost. 1984 Apr 30;51(2):182-5 - PubMed
    1. Br J Haematol. 1985 Jun;60(2):315-22 - PubMed
    1. Lancet. 1983 Jan 15;1(8316):84-7 - PubMed

Publication types

Substances